Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
Open Access
- 1 April 2021
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 62 (4) , 3
Abstract
Purpose: The purpose of this study was to determine whether YAP/TAZ activation in uveal melanoma (UM) and the susceptibility of melanoma cell lines to YAP/TAZ inhibition by verteporfin (VP) is related to the tumor's genetic background. Methods: Characteristics of 144 patients with enucleated UM were analyzed together with mRNA expression levels of YAP/TAZ-related genes (80 patients from the The Cancer Genome Atlas [TCGA] project and 64 patients from Leiden, The Netherlands). VP was administered to cell lines 92.1, OMM1, Mel270, XMP46, and MM28 (UM), CRMM1 and CRMM2 (conjunctival melanoma), and OCM3 (cutaneous melanoma). Viability, growth speed, and expression of YAP1-related proteins were assessed. Results: In TCGA data, high expression of YAP1 and WWTR1 correlated with the presence of monosomy 3 (P = 0.009 and P < 0.001, respectively) and BAP1-loss (P = 0.003 and P = 0.001, respectively) in the primary UM; metastasis development correlated with higher expression of YAP1 (P = 0.05) and WWTR1 (P = 0.003). In Leiden data, downstream transcription factor TEAD4 was increased in cases with M3/BAP1-loss (P = 0.002 and P = 0.006) and related to metastasis (P = 0.004). UM cell lines 92.1, OMM1, and Mel270 (GNAQ/11-mutation, BAP1-positive) and the fast-growing cell line OCM3 (BRAF-mutation) showed decreased proliferation after exposure to VP. Two slow-growing UM cell lines XMP46 and MM28 (GNAQ/11-mutation, BAP1-negative) were not sensitive to VP, and neither were the two conjunctival melanoma cell lines (BRAF/NRAS-mutation). Conclusions: High risk UM showed an increased expression of YAP/TAZ-related genes. Although most UM cell lines responded in vitro to VP, BAP1-negative and conjunctival melanoma cell lines did not. Not only the mutational background, but also cell growth rate is an important predictor of response to YAP/TAZ inhibition by VP.Keywords
This publication has 68 references indexed in Scilit:
- Identification of Serum-Derived Sphingosine-1-Phosphate as a Small Molecule Regulator of YAPChemistry & Biology, 2012
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Frequent Mutation of BAP1 in Metastasizing Uveal MelanomasScience, 2010
- Mutations inGNA11in Uveal MelanomaNew England Journal of Medicine, 2010
- Lack of OncogenicGNAQMutations in Melanocytic Lesions of the Conjunctiva as Compared to Uveal MelanomaInvestigative Ophthalmology & Visual Science, 2010
- Time trends in the incidence of conjunctival melanoma in SwedenBritish Journal of Ophthalmology, 2009
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24American Journal of Ophthalmology, 2004
- Melanomas that develop within the eye inhibit lymphocyte proliferationInternational Journal of Cancer, 1997
- Establishment and characterization of an uveal‐melanoma cell lineInternational Journal of Cancer, 1995